Paris, 29 April 2022 – 6.00 pm CEST – Advicenne (Euronext Growth Paris ALDVI – FR0013296746), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces that its 2021 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF).
